Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATARI: Ceralasertib +/- Olaparib or Durvalumab in Gynaecological Cancers
NCT04065269Phase 2Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ceralasertib in gynecological cancer, sponsored by The Institute of Cancer Research. Started Nov 2019; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on NCT04065269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065269.